1. Home
  2. CARA

CARA

Cara Therapeutics Inc.

Logo Cara Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-19-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.

Founded: 2004 Country:
United States
United States
Employees: N/A City: STAMFORD
Market Cap: 38.8M IPO Year: 2014
Target Price: $9.79 AVG Volume (30 days): 660.7K
Analyst Decision: Strong Buy Number of Analysts: 7
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.19 EPS Growth: N/A
52 Week Low/High: $0.50 - $4.67 Next Earning Date: 05-13-2024
Revenue: $20,968,000 Revenue Growth: -49.92%
Revenue Growth (this year): -68.43% Revenue Growth (next year): -29.34%

Share on Social Networks: